Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 94 Debt-to-EBITDA is 0.26 as of Mar. 2026, which is 80% below its 10-year median of 1.30. GuruFocus rates BXMPY with a GF Score™ of 94/100. The stock has 5 warning signs investors should review. Among 692 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 79.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Beximco Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
BXMPY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.41 Med: 1.3 Max: 2.79
Current: 0.24
During the past 13 years, the highest Debt-to-EBITDA Ratio of Beximco Pharmaceuticals was 2.79. The lowest was 0.41. And the median was 1.30.
BXMPY's Debt-to-EBITDA is ranked better than 79.77% of 692
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs BXMPY: 0.24
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Beximco Pharmaceuticals Debt-to-EBITDA Related Terms
Beximco Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BXMPY vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Beximco Pharmaceuticals (BXMPY) has a Debt-to-EBITDA of 0.26 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Beximco Pharmaceuticals. This is 80% below median its historical median of 1.30. Over the past decade, Beximco Pharmaceuticals' Debt-to-EBITDA has ranged from 0.41 to 2.79. According to the industry distribution chart, Beximco Pharmaceuticals ranks #140 out of 692 companies in the Drug Manufacturers industry, placing it in the top 20.2%.
Is Beximco Pharmaceuticals' Debt-to-EBITDA too high?
Beximco Pharmaceuticals' current Debt-to-EBITDA of 0.26 is 80% below median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 2.79. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Beximco Pharmaceuticals' value of 0.26 is 84.5% below this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #140 out of 692 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #140 out of 692 companies for Debt-to-EBITDA. This places Beximco Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.68. Beximco Pharmaceuticals' value of 0.26 is 84.5% below this benchmark. Historically, Beximco Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.41 to 2.79 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 1.68, Beximco Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Debt-to-EBITDA of 0.26 is 84.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Beximco Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Debt-to-EBITDA is 0.26, which is 80% below median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Debt-to-EBITDA of 0.26. The current Debt-to-EBITDA is 0.26, which is 80% below median its 10-year median of 1.30 and 84.5% below the Drug Manufacturers industry median of 1.68. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Debt-to-EBITDA is 0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
